Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research    » Alternative Medicine    » Beta Cells    » Cause    » Cells    » Children    » Complications    » Control    » Cure    » Diagnosis    » Drugs    » Elderly    » Genes    » Immune Cells    » Inhaled Insulin    » Insulin    » Islet Cells    » Neuropathy    » Obesity    » Oral Insulin    » Other Diseases    » Pets    » Pre-Diabetes    » Prevention    » Research    » Retinopathy    » Risk Factors    » Stem Cells    » Technology    » Testing    » Transplants    » Treatments    » Trials    » Type 1    » Type 2 Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Research » Testing

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Rimonabant (Accomplia) to Treat Obesity and Improve Glycemic Control Approved in Mexico Posted: Wednesday, November 22, 2006

Accomplia is now approved in Europe and Mexico, US next?

Novartis’s Diabetes Drug Galvus Will Be Delayed Posted: Wednesday, November 22, 2006

A U.S. decision on approving Novartis AG's key diabetes drug Galvus has been delayed by three months after the firm asked the Food and Drug Administration to consider new clinical trials data.

Januvia™ Works For for First and Second-Line Management of Type 2 Diabetes Posted: Thursday, November 16, 2006

The FDA has approved sitagliptin for use with diet and exercise or in combination with metformin or the TZDs to improve glycemic control in adult patients with type 2 diabetes.

Patients Miscode Monitors 16% of the Time Causing Faulty Readings Posted: Thursday, November 16, 2006

When persons with diabetes use miscoded blood glucose meters to determine how much insulin to take, significant errors in insulin dose can result that may potentially lead to short- and long-term health complications.

Acomplia ™(Rimonabant) Receives 1st Marketing Authorization in North America Posted: Thursday, November 16, 2006

Acomplia™ (rimonabant) approved in Mexico to treat obese/overweight patients with associated type 2 diabetes or dyslipidemia or to help them improve glycemic control on background of conventional antidiabetic treatment.

Born in the USA, One in Three Will Develop Diabetes Posted: Thursday, November 09, 2006

Fifty-four million Americans - that’s one in six of us -- have pre-diabetes and most don’t even realize it.

RESULTS IN! The Most Effective and Safe Method for Diabetes Prevention IS……. Posted: Thursday, November 09, 2006

Lifestyle Intervention Remains the Most Effective and Safe Method for Diabetes Prevention.

Importance of Fasting Hyperglycemia Dependent on HbA1c Posted: Thursday, November 09, 2006

Study concluded that the contribution of fasting hyperglycemia was greater in patients with increased HbA1c.

Switch To Insulin Pen Improves Clinical Outcomes And Reduces Medical Costs Posted: Thursday, November 02, 2006

Total all-cause annual treatment costs reduced by $1590 per patient.

Importance of Fasting Hyperglycemia Varies, Depending on HbA1c Posted: Wednesday, October 25, 2006

Treating fasting blood sugars when the A1c is elevated, has a greater impact on the resulting A1c.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.